BNT-325 by BioNTech for Malignant Mesothelioma: Likelihood of Approval

BNT-325 is under clinical development by BioNTech and currently in Phase II for Malignant Mesothelioma.

Evidation, USC Partner to Integrate Wearables Dataset for Healthy Aging Study

What You Should Know: Evidation, the company creating new ways to measure and improve health in everyday life, today announced a partnership with USC’s Dornsife Center

September 19, 2023

Laxxon Medical joins German Accelerator’s Southeast Asia Market Access Class of 2023, marking the Company’s inaugural globalization venture – Biotech Investments

New York, 11/16/2023 / 08:01, EST/EDT – EQS Newswire – Laxxon Medical NEW YORK, NY / ACCESSWIRE / November 16, 2023 / Pharmaceutical 3D screen

November 17, 2023

Change Healthcare cyberattack drives 2024 into another record year for health data breaches

As many as 172 million individuals — more than half the population of the United States — may have been impacted by large health data

December 5, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.